Mod GRF 1-29 & Ipamorelin Blend – 10MG

What Is the Mod GRF 1-29 & Ipamorelin Blend?

The Ipamorelin peptide has been studied for its potential as a growth hormone secretagogue (GHS). This synthetic pentapeptide is thought to operate in a manner akin to Growth Hormone Releasing Peptides (GHRPs) and may simulate the natural action of the hunger hormone, ghrelin. Specifically, it is believed that Ipamorelin may activate ghrelin receptors in the anterior pituitary gland, also known as Growth Hormone Secretagogue Receptors 1 Alpha (GHS-R1a). This makes it a notably selective secretagogue and a strong agonist for the growth hormone/ghrelin secretagogue receptor.

What sets Ipamorelin apart is its selectivity, as it does not appear to influence the release of other hormones from the pituitary gland, such as prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), or Adrenocorticotropic hormone (ACTH). Modified GRF (1-29) peptide, also known as Mod GRF 1-29, is a synthetic analog of natural growth hormone-releasing hormone (GHRH). Comprising the initial 29 amino acids of the native hormone, this analog appears to stimulate GHRH receptors located in the somatotroph cells of the anterior pituitary gland, thereby facilitating the release of growth hormone. While it shares structural similarities with GRF 1-29, Mod GRF 1-29 has been slightly altered by replacing four amino acids in its original sequence. These adjustments seem to improve the peptide’s pharmacokinetic properties. When presented together as a blend, these peptides appear to yield synergistic results, possibly stimulating the pituitary gland and triggering the release of growth hormone.

 

Specifications⁽¹⁾⁽²⁾

Name	Mod GRF 1-29 & Ipamorelin Blend
Amount per vial	10 mg: Mod GRF 1-29 (CJC-1295 without DAC) 5 mg, Ipamorelin 5 mg
Other known names	Mod GRF 1-29: Modified GRF (1-29), CJC-1295 without DAC; Ipamorelin: NNC 26-0161
Sequence	Mod GRF 1-29: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2; Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular formula	Mod GRF 1-29: C152H252N44O42; Ipamorelin: C38H49N9O5
Molecular weight	Mod GRF 1-29: 3367.9 g/mol; Ipamorelin: 711.9 g/mol
CAS number	Mod GRF 1-29: 863288-34-0; Ipamorelin: 170851-70-4
Synthesis	Solid-phase peptide synthesis, US
Form	Lyophilized powder
Purity	>99% (HPLC)
Storage	−20 °C, dry, protected from light
SKU	P-MODGRFIPAM-10

 

What Does Research Show About the Mod GRF 1-29 & Ipamorelin Blend?

How Selective Is Ipamorelin for Growth Hormone?

Key finding: In lab models, Ipamorelin released growth hormone with a potency and efficacy similar to GHRP-6, but unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol, even at more than 200 times the amount needed for half-maximal growth hormone release; FSH, LH, prolactin and TSH were not affected.⁽³⁾

A 1998 study⁽³⁾ was carried out where these growth hormone secretagogues were presented in the rat pituitary gland as well as in anesthetized rats and conscious swine. Results of all three studies suggested that these peptides are agonists of GHRP-like receptors, as they bind to these receptors and help secrete higher concentrations of growth hormone. While some growth hormone secretagogues also appeared to trigger increased levels of other hormones such as cortisol and ACTH, Ipamorelin appeared to exhibit selectivity towards growth hormones only, suggesting that these peptides may be particular in their functions.

In one 1999 clinical study,⁽⁴⁾ eight test subjects were enrolled to examine the potential of growth hormone secretagogues at different concentrations. The concentrations were presented at regular intervals for up to two hours. After the study was completed, the concentration of growth hormones appeared to have significantly risen throughout the study period.

How Potent Is Mod GRF 1-29 Compared With GRF 1-29?

In this preliminary study,⁽⁵⁾ experimental rats were examined after being introduced to GHRH peptide analogs such as Modified GRF 1-29 peptide. The results suggested that the peptide may be considerably more potent than regular GRF 1-29.

How May the Two Peptides Act on the Pituitary Gland?

When Mod GRF 1-29 interacts with GHRH receptors on the somatotroph cells of the anterior pituitary gland, it is theorized to act as a catalyst for ensuing cellular activities that may contribute to the release of growth hormone. This interaction is thought to set off a chain of intracellular signaling events. One such signaling route that seems to be engaged is the adenylyl cyclase pathway, potentially leading to the transformation of ATP (adenosine triphosphate) into cAMP (cyclic adenosine monophosphate).⁽⁶⁾ The subsequent elevation in cAMP levels is speculated to activate protein kinase A (PKA), which in turn may result in the phosphorylation of various proteins. Among these proteins are the voltage-dependent calcium channels located on the cell membrane. The phosphorylation of these channels is conjectured to facilitate the influx of calcium ions into the somatotrophic cells. Elevated levels of intracellular calcium are considered to be a key factor in the subsequent stages that may lead to growth hormone release. It is further theorized that these high calcium concentrations within the cell could prompt the secretory vesicles in the somatotroph cells to release growth hormone into the bloodstream.

It seems that Ipamorelin may also engage with cells in the front part of the pituitary gland by targeting the N-terminal region of GHS-R1a. This region contains specific binding sites that are likely sensitive to particular sequences in the secretagogue. When Ipamorelin encounters this receptor, it may form a temporary bond, facilitated by hydrogen bonds and van der Waals interactions. This transient bonding may induce a conformational change in the receptor, potentially triggering intracellular signaling pathways, predominantly those associated with G-proteins.⁽⁷⁾ Specifically, GHS-R1a is thought to collaborate with a specialized subunit of G-proteins known as Gαq/11. Gαq/11 is believed to interact with PLC, which may then cleave a lipid molecule called phosphatidylinositol 4,5-bisphosphate (PIP2) into two secondary messengers: IP3 (Inositol trisphosphate) and DAG (Diacylglycerol). IP3 may bind to specific sites on an organelle known as the endoplasmic reticulum, possibly leading to the release of calcium ions (Ca2+) and activation of proteins that facilitate the secretion of growth hormone from pituitary cells.⁽⁸⁾

What Does Research Suggest About Gastric Emptying?

Key finding: In a lab model of postoperative ileus, Ipamorelin accelerated gastric emptying through a ghrelin receptor-mediated increase in gastric contractility.⁽⁹⁾

In a particular study, scientists explored how Ipamorelin might influence gastric function, specifically focusing on its potential to accelerate gastric emptying. They used a specialized method to measure gastric emptying, which involves tracking the percentage of radioactivity remaining in the stomach 15 minutes after introducing a specific substance via intragastric gavage. The team noted that the surgical procedures performed on the abdomen could have contributed to a slower rate of gastric emptying, especially evident in the control group that received a vehicle substance. Contrastingly, Ipamorelin seemed to significantly hasten the emptying process when compared to the control group. This led the researchers to consider the possibility that Ipamorelin could enhance the speed of gastric emptying. Further investigations were carried out to understand the compound’s impact on the contractile behavior of gastric smooth muscles, which were stimulated by acetylcholine and electrical field stimulation. The findings indicated that surgical intervention and manipulation of the intestines might substantially suppress the contractile responses of these muscles to both stimuli. Interestingly, this suppression appeared to be counteracted by Ipamorelin or ghrelin. This raises the speculative notion that Ipamorelin may not only stimulate the contractility of gastric smooth muscles but also potentially negate the inhibitory action induced by certain surgical procedures.⁽⁹⁾

How May Ipamorelin Affect Appetite and Body Fat?

Key finding: In growth hormone-deficient and growth hormone-intact lab models, Ipamorelin increased body weight by about 15% within 2 weeks and raised fat pad weight relative to body weight, together with food intake and leptin, through mechanisms independent of growth hormone.⁽¹⁰⁾

The potential impact of Ipamorelin on ghrelin receptors suggests it may possibly boost appetite and, maybe, contribute to weight gain. A study indicates that experimental subjects experienced an approximate 15% increase in body weight when exposed to Ipamorelin.⁽¹⁰⁾ Researchers theorize that this compound may have proportionally increased fat pad weights relative to overall body mass.⁽¹⁰⁾ As a result, dual-energy X-ray absorptiometry (DEXA) measurements may show a relative uptick in body fat. Additionally, data suggests that Ipamorelin may have raised levels of serum leptin, a hormone implicated in regulating energy and appetite. This leads scientists to hypothesize that increased food intake may be a factor in the observed weight gain among the Ipamorelin groups. They commented that “GHSs increase body fat by GH-independent mechanisms that may include increased feeding.”

What Does Research Suggest About Bone Mineral Content?

Key finding: In 13-week-old female lab models, continuous Ipamorelin for 12 weeks increased body weight and tibial and vertebral bone mineral content measured by DXA; the cortical gain came from a larger cross-sectional bone area, while volumetric bone mineral density was unchanged.⁽¹¹⁾

In a study involving murine models, Ipamorelin and a control substance were introduced to assess their potential on bone mass. Real-time DEXA was employed to monitor changes in bone mineral content, focusing on specific regions like the femur and L6 vertebrae. After the research period, mid-diaphyseal peripheral quantitative computed tomography (pQCT) scans were conducted on the femurs of the subjects. Initial findings indicate that Ipamorelin may be linked to a potential increase in weight as well as a possible uptick in bone mineral content in the tibia and vertebrae, as revealed by DEXA, when compared to the control group. Moreover, pQCT data suggests that the observed rise in cortical BMC may be attributable to an enlargement in the bone’s cross-sectional area.⁽¹¹⁾ The researchers also posited that “small stimulatory effects on linear bone growth may not have been detected statistically in the GH- and ipamorelin-treated groups”.

 

Certificate of Analysis

Batch / lot	C73663
Test date	4/2/2026
Testing laboratory	Vanguard Laboratory
Method	HPLC-UV/VIS (purity)
Purity result	99.02%
Full report	Download the Mod GRF 1-29 & Ipamorelin Blend COA (PDF)

Mod GRF 1-29 & Ipamorelin Blend is available for research and laboratory purposes only. We offer free shipping in the US for orders over $200. Please review our Terms and Conditions before ordering.

 

Frequently Asked Questions

 

References:

1. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC
2. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin
3. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
4. Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
5. Schally, A. V., Zhang, X., Cai, R., Hare, J. M., Granata, R., & Bartoli, M. (2019). Actions and potential therapeutic applications of growth hormone-releasing hormone agonists. Endocrinology, 160(7), 1600–1612. https://doi.org/10.1210/en.2019-00111
6. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
7. Yin, Y., Li, Y., & Zhang, W. (2014). The growth hormone secretagogue receptor: its intracellular signaling and regulation. International journal of molecular sciences, 15(3), 4837–4855. https://doi.org/10.3390/ijms15034837
8. Bill, C. A., & Vines, C. M. (2020). Phospholipase C. Advances in experimental medicine and biology, 1131, 215–242. https://doi.org/10.1007/978-3-030-12457-1_9
9. Greenwood-Van Meerveld, B., Tyler, K., Mohammadi, E., & Pietra, C. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 4, 149–155. https://doi.org/10.2147/JEP.S35396
10. Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065
11. Svensson, J., Lall, S., Dickson, S. L., Bengtsson, B. A., Rømer, J., Ahnfelt-Rønne, I., Ohlsson, C., & Jansson, J. O. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of endocrinology, 165(3), 569–577. https://doi.org/10.1677/joe.0.1650569

Related reading: Mod GRF 1-29 & Ipamorelin research on fat and bone cells and Mod GRF 1-29 vs CJC-1295 DAC.

Last updated Oct 30, 2026 · Scientific review: Dr. Dimitar Marinov, MD, PhD